Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Entrada Therapeutics Inc ( (TRDA) ) has issued an announcement.
On May 7, 2026, Entrada Therapeutics reported first-quarter 2026 results and unveiled positive topline data from Cohort 1 of its Phase 1/2 ELEVATE-44-201 trial of ENTR-601-44 in boys with Duchenne muscular dystrophy amenable to exon 44 skipping. Participants receiving 6 mg/kg of ENTR-601-44 showed statistically significant improvement in Time to Rise velocity and a favorable safety and tolerability profile, with only mild or moderate adverse events and no serious events or discontinuations.
The company said it remained on track to deliver multiple data readouts in 2026, including Cohort 1 results from its exon 45 program ELEVATE-45-201 midyear and additional ELEVATE-44-201 cohorts by year-end, while cash, cash equivalents and marketable securities of $254.9 million as of March 31, 2026 were expected to fund operations into the third quarter of 2027. First-quarter collaboration revenue dropped to $0.9 million from $20.6 million a year earlier as research activities on VX-670 wound down, while higher spending on Duchenne programs helped widen the net loss to $39.7 million, underscoring the company’s increasing reliance on clinical execution to support its valuation and long-term strategy in neuromuscular and genetic eye diseases.
The most recent analyst rating on (TRDA) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Entrada Therapeutics Inc stock, see the TRDA Stock Forecast page.
Spark’s Take on TRDA Stock
According to Spark, TipRanks’ AI Analyst, TRDA is a Neutral.
TRDA’s score is held back primarily by weak and volatile fundamentals—especially the sharp 2025 reversal into heavy losses and significant cash burn—despite a comparatively solid, low-leverage balance sheet. Technicals are supportive with a strong uptrend, but momentum is overbought, adding near-term risk. Valuation is difficult to assess given the negative P/E and lack of dividend yield data.
To see Spark’s full report on TRDA stock, click here.
More about Entrada Therapeutics Inc
Entrada Therapeutics, Inc. is a Boston-based clinical-stage biopharmaceutical company developing a new class of genetic medicines that target intracellular pathways previously considered inaccessible. Its lead oligonucleotide programs focus on treating Duchenne muscular dystrophy in patients amenable to exon 44, 45, 50 and 51 skipping, alongside partnered development of VX-670 for myotonic dystrophy type 1.
The company is also expanding a preclinical pipeline in ocular and metabolic diseases, including ENTR-801 for Usher syndrome type 2A and a second inherited retinal disease candidate expected to be named in the second half of 2026. Entrada’s programs span the U.S., U.K. and EU, positioning it in the competitive neuromuscular and inherited retinal disease markets, where unmet medical need remains high.
Average Trading Volume: 208,068
Technical Sentiment Signal: Buy
Current Market Cap: $622.3M
For an in-depth examination of TRDA stock, go to TipRanks’ Overview page.